Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Replimune (REPL) has a market cap of $0.59 billion USD. According to our data, Replimune is ranked No.5747 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $0.59 B |
-36.28%
|
| Dec 31, 2024 | $0.93 B |
43.65%
|
| Dec 29, 2023 | $0.65 B |
-69.01%
|
| Dec 30, 2022 | $2.09 B |
0.37%
|
| Dec 31, 2021 | $2.09 B |
-28.96%
|
| Dec 31, 2020 | $2.94 B |
165.85%
|
| Dec 31, 2019 | $1.10 B |
43.50%
|
| Dec 31, 2018 | $0.77 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
UK
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Moderna
MRNA
|
$10.14 B |
-0.001 M
|
USA
|
| Market Cap | = | REPL Stock Price | * | REPL Shares Outstanding |
| = | $7.71 | * | 77.01 M | |
| = | $0.59 B |